Athersys has reached straight for the big ax in an attempt to chop down on costs. Weeks after the failure of a stem cell trial tanked its stock, the biotech outlined plans to reduce headcount by 70% ...
As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NAS: ATHX) is particularly vulnerable to big drops in its share price. That's ...
Athersys Inc., the financially strapped cell therapy and regenerative medicine company in Cleveland, ended 2023 with considerable uncertainty about 2024. The company said in a Dec. 22 filing with the ...
Athersys Inc. (Nasdaq: ATHX) is making some headway in its effort to find new sources of financing to support the business. The Cleveland-based biotechnology and regenerative medicine company on ...
Today, we delve into the financials of Athersys Inc (NASDAQ:ATHX), a biotechnology company with a daily gain of 12.75%. Despite this gain, the company has suffered a 3-month loss of 46.82% and a Loss ...
CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. is in line for up to $111 million in revenue through an agreement with a Pfizer Inc. unit to develop and market a stem cell therapy for ...
Stem cell therapy developer Athersys (NASDAQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a phase 2 clinical trial for inflammatory bowel disease. The trial marks an “important ...
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care ...
Shares of Athersys (NASDAQ: ATHX) jumped more than 18% today after the company announced that a collaboration partner has enrolled the first patient in a clinical trial in Japan. Healios is evaluating ...
CLEVELAND, Ohio--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation ...
Recent market movements have been brutal for small biotech Athersys. As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results